

# Nicolas Wentzensen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7779787/publications.pdf>

Version: 2024-02-01

292  
papers

18,689  
citations

15001

68  
h-index

20023

121  
g-index

297  
all docs

297  
docs citations

297  
times ranked

21482  
citing authors

#	ARTICLE	IF	CITATIONS
1	Using Natural Language Processing to Improve Discrete Data Capture From Interpretive Cervical Biopsy Diagnoses at a Large Health Care Organization. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 222-226.	1.2	1
2	Cohort Profile: The Ovarian Cancer Cohort Consortium (OC3). <i>International Journal of Epidemiology</i> , 2022, 51, e73-e86.	0.9	5
3	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 443-452.	1.1	2
4	Reproductive factors do not influence survival with ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , cebp.1091.2021.	1.1	1
5	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
6	Inflammatory markers in women with reported benign gynecologic pathology: an analysis of the prostate, lung, colorectal and ovarian cancer screening trial.. <i>Annals of Epidemiology</i> , 2022, 68, 1-8.	0.9	1
7	Cervical Precancers and Cancers Attributed to HPV Types by Race and Ethnicity: Implications for Vaccination, Screening, and Management. <i>Journal of the National Cancer Institute</i> , 2022, 114, 845-853.	3.0	12
8	What Contributes to Pregnancy Complications Among Women With Cervical Intraepithelial Neoplasia Grade 3?. <i>Annals of Internal Medicine</i> , 2022, 175, 293-294.	2.0	0
9	Automated Evaluation of p16/Ki-67 Dual-Stain Cytology as a Biomarker for Detection of Anal Precancer in Men Who Have Sex With Men and Are Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2022, 75, 1565-1572.	2.9	6
10	Meta-analysis of agreement/concordance statistics in studies comparing self-collected samples for HPV testing in cervical cancer screening. <i>International Journal of Cancer</i> , 2022, 151, 308-312.	2.3	31
11	Reply to: Comments on "Meta-analysis of agreement/concordance statistics in studies comparing self-collected samples for HPV testing in cervical cancer screening". <i>International Journal of Cancer</i> , 2022, 151, 484-487.	2.3	0
12	Computable Guidelines and Clinical Decision Support for Cervical Cancer Screening and Management to Improve Outcomes and Health Equity. <i>Journal of Women's Health</i> , 2022, 31, 462-468.	1.5	14
13	Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. <i>JAMA Oncology</i> , 2022, 8, 895.	3.4	57
14	Different human papillomavirus types share early natural history transitions in immunocompetent women. <i>International Journal of Cancer</i> , 2022, 151, 920-929.	2.3	5
15	Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management. <i>International Journal of Cancer</i> , 2022, 151, 1142-1149.	2.3	12
16	Accuracy and Efficiency of Deep-Learning-Based Automation of Dual Stain Cytology in Cervical Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2021, 113, 72-79.	3.0	82
17	The Orderly Incorporation of Continuing Technologic Advances Into Cervical Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2021, 113, 231-233.	3.0	3
18	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. <i>Journal of the National Cancer Institute</i> , 2021, 113, 301-308.	3.0	8

#	ARTICLE	IF	CITATIONS
19	Trends in hysterectomy-corrected uterine cancer mortality rates during 2002 to 2015: mortality of nonendometrioid cancer on the rise?. <i>International Journal of Cancer</i> , 2021, 148, 584-592.	2.3	5
20	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. <i>International Journal of Cancer</i> , 2021, 148, 307-319.	2.3	35
21	Risk of cervical precancer and cancer among uninsured and underserved women from 2009 to 2017. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 366.e1-366.e32.	0.7	14
22	Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2021, 124, 831-841.	2.9	39
23	Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. <i>International Journal of Cancer</i> , 2021, 148, 2068-2078.	2.3	14
24	Summary of Current Guidelines for Cervical Cancer Screening and Management of Abnormal Test Results: 2016-2020. <i>Journal of Women's Health</i> , 2021, 30, 5-13.	1.5	31
25	Cervical Screening Performance. <i>American Journal of Clinical Pathology</i> , 2021, 155, 616-620.	0.4	3
26	Genital powder use and risk of uterine cancer: A pooled analysis of prospective studies. <i>International Journal of Cancer</i> , 2021, 148, 2692-2701.	2.3	4
27	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. <i>Cancer Research</i> , 2021, 81, 3134-3143.	0.4	8
28	Treatment approaches for women with positive cervical screening results in low-and middle-income countries. <i>Preventive Medicine</i> , 2021, 144, 106439.	1.6	10
29	Cervical Cancer Screening-Past, Present, and Future. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 432-434.	1.1	8
30	Hidden mover-stayer model for disease progression accounting for misclassified and partially observed diagnostic tests: Application to the natural history of human papillomavirus and cervical precancer. <i>Statistics in Medicine</i> , 2021, 40, 3460-3476.	0.8	1
31	The relationship of human papillomavirus and cytology co-testing results with endometrial and ovarian cancer diagnoses. <i>Gynecologic Oncology</i> , 2021, 161, 297-303.	0.6	3
32	Associations between Genetically Predicted Circulating Protein Concentrations and Endometrial Cancer Risk. <i>Cancers</i> , 2021, 13, 2088.	1.7	10
33	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. <i>Carcinogenesis</i> , 2021, 42, 785-793.	1.3	6
34	Genetic and Epigenetic Variations of HPV52 in Cervical Precancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6463.	1.8	9
35	Quantifying procedural pain associated with office gynecologic tract sampling methods. <i>Gynecologic Oncology</i> , 2021, 162, 128-133.	0.6	6
36	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 1408-1417.	2.2	9

#	ARTICLE	IF	CITATIONS
37	Liquid Biopsy for Cancer Detection: Clinical and Epidemiologic Considerations. <i>Clinical Cancer Research</i> , 2021, 27, 5733-5735.	3.2	4
38	Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence. <i>Gynecologic Oncology</i> , 2021, 163, 199-208.	0.6	12
39	2020 list of human papillomavirus assays suitable for primary cervical cancer screening. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1083-1095.	2.8	116
40	Tao brush endometrial cytology is a sensitive diagnostic tool for cancer and hyperplasia among women presenting to clinic with abnormal uterine bleeding. <i>Cancer Medicine</i> , 2021, 10, 7040-7047.	1.3	8
41	Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29,900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. <i>Lancet HIV</i> , 2021, 8, e531-e543.	2.1	77
42	Phylogenomic Analysis of Human Papillomavirus Type 31 and Cervical Carcinogenesis: A Study of 2093 Viral Genomes. <i>Viruses</i> , 2021, 13, 1948.	1.5	7
43	Impact of COVID-19 on cervical cancer screening: Challenges and opportunities to improving resilience and reduce disparities. <i>Preventive Medicine</i> , 2021, 151, 106596.	1.6	68
44	STRIDES - Studying Risk to Improve Disparities in Cervical Cancer in Mississippi – Design and baseline results of a Statewide Cohort Study. <i>Preventive Medicine</i> , 2021, 153, 106740.	1.6	9
45	Rethinking Cervical Cancer Screening in Brazil Post COVID-19: A Global Opportunity to Adopt Higher Impact Strategies. <i>Cancer Prevention Research</i> , 2021, 14, 919-926.	0.7	5
46	Multisite Clinical Validation of Isothermal Amplification-Based SARS-CoV-2 Detection Assays Using Different Sampling Strategies. <i>Microbiology Spectrum</i> , 2021, 9, e0084621.	1.2	4
47	Development of a Large Biorepository of Cervical Specimens for the Improving Risk Informed HPV Screening Study (IRIS). <i>Journal of Clinical Virology</i> , 2021, 145, 105014.	1.6	2
48	Age-specific prevalence of human papillomavirus and abnormal cytology at baseline in a diverse statewide prospective cohort of individuals undergoing cervical cancer screening in Mississippi. <i>Cancer Medicine</i> , 2021, 10, 8641-8650.	1.3	9
49	The IARC Perspective on Cervical Cancer Screening. <i>New England Journal of Medicine</i> , 2021, 385, 1908-1918.	13.9	125
50	The Improving Risk Informed HPV Screening (IRIS) Study: Design and Baseline Characteristics. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0865.2021.	1.1	3
51	Absolute risks of cervical precancer among women who fulfill existing guidelines based on HPV and cytology cotesting. <i>International Journal of Cancer</i> , 2020, 146, 617-626.	2.3	5
52	Response to Pretorius and Belinson. <i>Journal of the National Cancer Institute</i> , 2020, 112, 115-116.	3.0	0
53	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1003-1012.	3.0	59
54	Association of Powder Use in the Genital Area With Risk of Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 49.	3.8	41

#	ARTICLE	IF	CITATIONS
55	Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 682-688.	0.6	20
56	Relationships of p16 Immunohistochemistry and Other Biomarkers With Diagnoses of Cervical Abnormalities: Implications for LAST Terminology. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 725-734.	1.2	30
57	A prospective clinical cohort study of women at increased risk for endometrial cancer. <i>Gynecologic Oncology</i> , 2020, 156, 169-177.	0.6	17
58	Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. <i>Infectious Agents and Cancer</i> , 2020, 15, 60.	1.2	27
59	A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. <i>EClinicalMedicine</i> , 2020, 22, 100293.	3.2	109
60	Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer. <i>Cancer Causes and Control</i> , 2020, 31, 869-879.	0.8	18
61	Ovarian Cancer Risk Factor Associations by Primary Anatomic Site: The Ovarian Cancer Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2010-2018.	1.1	6
62	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2735-2739.	1.1	6
63	Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies. <i>Statistics in Medicine</i> , 2020, 39, 4405-4420.	0.8	4
64	A demonstration of automated visual evaluation of cervical images taken with a smartphone camera. <i>International Journal of Cancer</i> , 2020, 147, 2416-2423.	2.3	46
65	Challenges Associated With Cervical Cancer Screening and Management in Obese Women. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 184-191.	0.9	9
66	Genital Powder Use and Ovarian Cancer—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2096.	3.8	0
67	Genome-Wide Gene–Gene Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1784-1791.	1.1	5
68	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	3.2	43
69	Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral–host interaction with implications for disease intervention. <i>International Journal of Cancer</i> , 2020, 147, 2677-2686.	2.3	44
70	A study of the risks of CIN3+ detection after multiple rounds of HPV testing: Results of the 15-year cervical cancer screening experience at Kaiser Permanente Northern California. <i>International Journal of Cancer</i> , 2020, 147, 1612-1620.	2.3	15
71	Racial differences in HPV type 16 prevalence in women with ASCUS of the uterine cervix. <i>Cancer Cytopathology</i> , 2020, 128, 528-534.	1.4	12
72	2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 102-131.	0.9	608

#	ARTICLE	IF	CITATIONS
73	Risk Estimates Supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 132-143.	0.9	116
74	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. <i>Gynecologic Oncology</i> , 2020, 158, 702-709.	0.6	15
75	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. <i>Cancer Research</i> , 2020, 80, 4004-4013.	0.4	5
76	The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3). <i>Cancer Research</i> , 2020, 80, 1210-1218.	0.4	35
77	Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease. <i>Cancer Causes and Control</i> , 2020, 31, 309-320.	0.8	16
78	Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. <i>Nature Communications</i> , 2020, 11, 886.	5.8	52
79	Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 636-642.	1.1	9
80	Identification of HPV genotypes causing cervical precancer using tissue-based genotyping. <i>International Journal of Cancer</i> , 2020, 146, 2836-2844.	2.3	13
81	Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 200-207.	1.1	11
82	Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 549.e1-549.e13.	0.7	40
83	2019 ASCCP Risk-Based Management Consensus Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 90-101.	0.9	66
84	A Study of Partial Human Papillomavirus Genotyping in Support of the 2019 ASCCP Risk-Based Management Consensus Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 144-147.	0.9	48
85	An Introduction to the 2019 ASCCP Risk-Based Management Consensus Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 87-89.	0.9	26
86	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2019, 79, 505-517.	0.4	49
87	Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. <i>Journal of the National Cancer Institute</i> , 2019, 111, 137-145.	3.0	43
88	Antibodies Against <i>Chlamydia trachomatis</i> and Ovarian Cancer Risk in Two Independent Populations. <i>Journal of the National Cancer Institute</i> , 2019, 111, 129-136.	3.0	56
89	Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Women's Health Initiative Observational Study. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz029.	1.4	30
90	Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes. <i>Journal of Infectious Diseases</i> , 2019, 220, 1609-1619.	1.9	17

#	ARTICLE	IF	CITATIONS
91	High Levels of C-Reactive Protein Are Associated with an Increased Risk of Ovarian Cancer: Results from the Ovarian Cancer Cohort Consortium. <i>Cancer Research</i> , 2019, 79, 5442-5451.	0.4	36
92	Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study. <i>Cancer Causes and Control</i> , 2019, 30, 1201-1211.	0.8	13
93	Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study. <i>International Journal of Cancer</i> , 2019, 145, 2051-2060.	2.3	15
94	Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2019, 48, 822-830.	0.9	22
95	Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. <i>Clinical Cancer Research</i> , 2019, 25, 5937-5946.	3.2	50
96	Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 1895-1908.	0.8	169
97	Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program. <i>JAMA Internal Medicine</i> , 2019, 179, 881.	2.6	98
98	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. <i>Cancer Medicine</i> , 2019, 8, 2503-2513.	1.3	6
99	Development of the TypeSeq Assay for Detection of 51 Human Papillomavirus Genotypes by Next-Generation Sequencing. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	27
100	Meta-analysis of the accuracy of p16 or p16/Ki-67 immunocytochemistry versus HPV testing for the detection of CIN2+/CIN3+ in triage of women with minor abnormal cytology. <i>Cancer Cytopathology</i> , 2019, 127, 169-180.	1.4	31
101	Circulating inflammation markers and colorectal adenoma risk. <i>Carcinogenesis</i> , 2019, 40, 765-770.	1.3	14
102	Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. <i>Papillomavirus Research (Amsterdam, Tj ETQq0 0 0 rgBT /Ovarlock 168f 50 297</i>		
103	Development and validation of circulating CA125 prediction models in postmenopausal women. <i>Journal of Ovarian Research</i> , 2019, 12, 116.	1.3	12
104	Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results. <i>Journal of the National Cancer Institute</i> , 2019, 111, 820-827.	3.0	20
105	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 557-567.	3.0	21
106	5-Year Prospective Evaluation of Cytology, Human Papillomavirus Testing, and Biomarkers for Detection of Anal Precancer in Human Immunodeficiency Virus-Positive Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2019, 69, 631-638.	2.9	29
107	An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2019, 111, 923-932.	3.0	249
108	Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women. <i>JAMA Oncology</i> , 2019, 5, 181.	3.4	79

#	ARTICLE	IF	CITATIONS
109	Prediagnostic Serum Levels of Fatty Acid Metabolites and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 189-197.	1.1	33
110	Childhood Overweight, Tallness, and Growth Increase Risks of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 183-188.	1.1	14
111	Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer. <i>Oncotarget</i> , 2019, 10, 2515-2529.	0.8	11
112	Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	18
113	Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1222-1228.	3.0	12
114	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. <i>British Journal of Cancer</i> , 2018, 118, 1123-1129.	2.9	15
115	Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening. <i>Journal of the National Cancer Institute</i> , 2018, 110, 501-508.	3.0	116
116	Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs. <i>International Journal of Cancer</i> , 2018, 143, 735-745.	2.3	124
117	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.	5.8	188
118	Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register. <i>Gynecologic Oncology</i> , 2018, 148, 547-552.	0.6	4
119	Accelerating cervical cancer control and prevention. <i>Lancet Public Health</i> , The, 2018, 3, e6-e7.	4.7	13
120	Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records. <i>Preventive Medicine</i> , 2018, 111, 429-435.	1.6	15
121	Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries. <i>Journal of the National Cancer Institute</i> , 2018, 110, 750-757.	3.0	28
122	Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 97-103.	0.9	5
123	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018, 33, 690-705.e9.	7.7	478
124	A prospective study of risk-based colposcopy demonstrates improved detection of cervical precancers. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 604.e1-604.e8.	0.7	23
125	Alcohol and oestrogen metabolites in postmenopausal women in the Women's Health Initiative Observational Study. <i>British Journal of Cancer</i> , 2018, 118, 448-457.	2.9	14
126	Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 174-182.	1.1	20



#	ARTICLE	IF	CITATIONS
127	Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1184-1191.	0.8	65
128	Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis. <i>Cancer Cytopathology</i> , 2018, 126, 950-958.	1.4	12
129	Population Testing for High Penetrance Genes: Are We There Yet?. <i>Journal of the National Cancer Institute</i> , 2018, 110, 687-689.	3.0	6
130	Strategies for screening and early detection of anal cancers: A narrative and systematic review and meta-analysis of cytology, HPV testing, and other biomarkers. <i>Cancer Cytopathology</i> , 2018, 126, 447-460.	1.4	72
131	Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women. <i>JAMA Internal Medicine</i> , 2018, 178, 1210.	2.6	233
132	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
133	Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer. <i>Annals of Internal Medicine</i> , 2018, 168, 20.	2.0	50
134	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. <i>PLoS ONE</i> , 2018, 13, e0197561.	1.1	9
135	HLA and KIR Associations of Cervical Neoplasia. <i>Journal of Infectious Diseases</i> , 2018, 218, 2006-2015.	1.9	22
136	Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , 2018, 9, 3166.	5.8	178
137	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	1.8	3
138	In Defense of a Simplified, Practical Colposcopic Terminology. <i>Journal of Lower Genital Tract Disease</i> , 2018, 22, 233-234.	0.9	0
139	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. <i>British Journal of Cancer</i> , 2017, 116, 524-535.	2.9	23
140	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. <i>International Journal of Cancer</i> , 2017, 140, 2422-2435.	2.3	25
141	Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. <i>Cancer Causes and Control</i> , 2017, 28, 429-435.	0.8	3
142	Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancer. <i>International Journal of Cancer</i> , 2017, 141, 701-710.	2.3	62
143	Trends in cervical cancer incidence in younger US women from 2000 to 2013. <i>Gynecologic Oncology</i> , 2017, 144, 391-395.	0.6	10
144	Preparing for the Next Round of ASCCP-Sponsored Cervical Screening and Management Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 87-90.	0.9	23

#	ARTICLE	IF	CITATIONS
145	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
146	Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium. <i>Cancer Research</i> , 2017, 77, 3951-3960.	0.4	48
147	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2017, 116, 1223-1228.	2.9	13
148	HPV-based cervical cancer screening- facts, fiction, and misperceptions. <i>Preventive Medicine</i> , 2017, 98, 33-35.	1.6	43
149	Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. <i>International Journal of Cancer</i> , 2017, 140, 2192-2200.	2.3	83
150	Improvement in 5-Year Survival Rates for the Most Common Types of Cancer, 1975-2012. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	18
151	From clinical epidemiology to practice recommendations: Knowledge gaps and uncertainty in the management of anal precancers. <i>Cancer</i> , 2017, 123, 4530-4534.	2.0	7
152	Evidence-Based Consensus Recommendations for Colposcopy Practice for Cervical Cancer Prevention in the United States. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 216-222.	0.9	71
153	ASCCP Colposcopy Standards: Risk-Based Colposcopy Practice. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 230-234.	0.9	56
154	Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines. <i>Journal of Lower Genital Tract Disease</i> , 2017, 21, 261-267.	0.9	55
155	Smoking and subsequent human papillomavirus infection: a mediation analysis. <i>Annals of Epidemiology</i> , 2017, 27, 724-730.e1.	0.9	33
156	Sitting, physical activity, and serum oestrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study. <i>British Journal of Cancer</i> , 2017, 117, 1070-1078.	2.9	14
157	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. <i>Cell</i> , 2017, 170, 1164-1174.e6.	13.5	221
158	Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women's Health Initiative Observational Study. <i>Breast Cancer Research</i> , 2017, 19, 28.	2.2	21
159	Genotyping for Human Papillomavirus Types 16 and 18 in Women With Minor Cervical Lesions. <i>Annals of Internal Medicine</i> , 2017, 166, 118.	2.0	53
160	Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. <i>International Journal of Cancer</i> , 2017, 140, 600-610.	2.3	48
161	Proof-of-principle study of a novel cervical screening and triage strategy: Computer-analyzed cytology to decide which HPV-positive women are likely to have ≥CIN2. <i>International Journal of Cancer</i> , 2017, 140, 718-725.	2.3	19
162	Distribution of cell types differs in Papanicolaou tests of squamous cell carcinomas and adenocarcinomas. <i>Journal of the American Society of Cytopathology</i> , 2017, 6, 10-15.	0.2	3

#	ARTICLE	IF	CITATIONS
163	Somatic Host Cell Alterations in HPV Carcinogenesis. <i>Viruses</i> , 2017, 9, 206.	1.5	55
164	Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States. <i>PLoS ONE</i> , 2017, 12, e0182359.	1.1	7
165	Defining the genetic susceptibility to cervical neoplasia—A genome-wide association study. <i>PLoS Genetics</i> , 2017, 13, e1006866.	1.5	105
166	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. <i>Oncotarget</i> , 2017, 8, 84579-84594.	0.8	23
167	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. <i>Oncotarget</i> , 2016, 7, 66328-66343.	0.8	88
168	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 884-895.	0.9	71
169	Reply to HPV test results provide useful risk stratification information in women with ASC—Pap test findings. <i>Cancer Cytopathology</i> , 2016, 124, 754-755.	1.4	0
170	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. <i>Human Molecular Genetics</i> , 2016, 25, 3600-3612.	1.4	17
171	Triage of ASC—: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer. <i>Cancer Cytopathology</i> , 2016, 124, 261-272.	1.4	25
172	Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations. <i>Obstetrics and Gynecology</i> , 2016, 128, 1248-1257.	1.2	22
173	Carcinogenic human papillomavirus infection. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16086.	18.1	615
174	Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. <i>Cancer Causes and Control</i> , 2016, 27, 737-748.	0.8	34
175	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016, 135, 741-756.	1.8	19
176	Response. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv390.	3.0	0
177	HPV16 Sublineage Associations With Histology-Specific Cancer Risk Using HPV Whole-Genome Sequences in 3200 Women. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw100.	3.0	147
178	Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1081-1089.	1.1	76
179	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016, 45, 1619-1630.	0.9	111
180	The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen. <i>Cancer</i> , 2016, 122, 3682-3686.	2.0	15

#	ARTICLE	IF	CITATIONS
181	Telomere structure and maintenance gene variants and risk of five cancer types. <i>International Journal of Cancer</i> , 2016, 139, 2655-2670.	2.3	43
182	A cohort study of cervical screening using partial HPV typing and cytology triage. <i>International Journal of Cancer</i> , 2016, 139, 2606-2615.	2.3	68
183	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	7.7	157
184	Genomic characterization of viral integration sites in HPV-related cancers. <i>International Journal of Cancer</i> , 2016, 139, 2001-2011.	2.3	113
185	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. <i>Nature Communications</i> , 2016, 7, 11843.	5.8	86
186	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
187	Biomarkers for Cervical Cancer Prevention Programs: The Long and Winding Road From Discovery to Clinical Use. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, 191-194.	0.9	7
188	Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. <i>Journal of Clinical Oncology</i> , 2016, 34, 2888-2898.	0.8	349
189	Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 648-656.	1.1	47
190	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. <i>British Journal of Cancer</i> , 2016, 115, 95-101.	2.9	39
191	Risk assessment to guide cervical screening strategies in a large Chinese population. <i>International Journal of Cancer</i> , 2016, 138, 2639-2647.	2.3	16
192	Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis. <i>Journal of Infectious Diseases</i> , 2016, 213, 1444-1454.	1.9	96
193	Triage of HPV positive women in cervical cancer screening. <i>Journal of Clinical Virology</i> , 2016, 76, S49-S55.	1.6	236
194	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 780-790.	1.1	10
195	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. <i>Cancer Epidemiology</i> , 2016, 41, 71-79.	0.8	20
196	Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. <i>Carcinogenesis</i> , 2016, 37, 188-196.	1.3	41
197	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. <i>Oncotarget</i> , 2016, 7, 69097-69110.	0.8	5
198	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	0.8	13

#	ARTICLE	IF	CITATIONS
199	A targeted genetic association study of epithelial ovarian cancer susceptibility. <i>Oncotarget</i> , 2016, 7, 7381-7389.	0.8	7
200	Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 819-827.	0.4	62
201	PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. <i>Cancer Causes and Control</i> , 2015, 26, 1729-1736.	0.8	31
202	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	0.6	22
203	Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening. <i>Journal of Lower Genital Tract Disease</i> , 2015, 19, 91-96.	0.9	64
204	Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. <i>BMC Infectious Diseases</i> , 2015, 15, 544.	1.3	40
205	Issues in optimising and standardising the accuracy and utility of the colposcopic examination in the HPV era. <i>Ecancermedicalscience</i> , 2015, 9, 530.	0.6	17
206	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.	1.1	44
207	Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. <i>PLoS ONE</i> , 2015, 10, e0143256.	1.1	13
208	Associations of Coffee Drinking with Systemic Immune and Inflammatory Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1052-1060.	1.1	59
209	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. <i>American Journal of Human Genetics</i> , 2015, 96, 487-497.	2.6	101
210	HPV16 CpG methyl-haplotypes are associated with cervix precancer and cancer in the Guanacaste natural history study. <i>Gynecologic Oncology</i> , 2015, 138, 94-100.	0.6	10
211	Risk factors for endometrial cancer in black and white women: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). <i>Cancer Causes and Control</i> , 2015, 26, 287-296.	0.8	40
212	Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance. <i>Gynecologic Oncology</i> , 2015, 136, 178-182.	0.6	374
213	Metabolic Syndrome and Risk of Endometrial Cancer in the United States: A Study in the SEER-Medicare Linked Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 261-267.	1.1	109
214	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
215	Cell-Cycle Protein Expression in a Population-Based Study of Ovarian and Endometrial Cancers. <i>Frontiers in Oncology</i> , 2015, 5, 25.	1.3	19
216	The Pill's gestation: from birth control to cancer prevention. <i>Lancet Oncology</i> , The, 2015, 16, 1004-1006.	5.1	7

#	ARTICLE	IF	CITATIONS
217	Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2015, 1, 3-11.	4.5	75
218	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1574-1584.	1.1	28
219	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276.	3.2	33
220	A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. <i>Gynecologic Oncology</i> , 2015, 138, 573-578.	0.6	49
221	The Role of Human Papillomavirus Genotyping in Cervical Cancer Screening: A Large-Scale Evaluation of the cobas HPV Test. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1304-1310.	1.1	44
222	Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. <i>Gynecologic Oncology</i> , 2015, 137, 14-22.	0.6	79
223	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. <i>Gynecologic Oncology</i> , 2015, 136, 542-548.	0.6	15
224	Hormone therapy: short-term relief, long-term consequences. <i>Lancet, The</i> , 2015, 385, 1806-1808.	6.3	22
225	Attributing Oncogenic Human Papillomavirus Genotypes to High-grade Cervical Neoplasia. <i>American Journal of Surgical Pathology</i> , 2015, 39, 496-504.	2.1	31
226	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. <i>Nature Communications</i> , 2015, 6, 8234.	5.8	63
227	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, 1341-1353.	1.3	24
228	Towards therapeutic vaccination against cervical precancer?. <i>Lancet, The</i> , 2015, 386, 2036-2038.	6.3	1
229	Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3255-64.	3.3	197
230	p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv257.	3.0	130
231	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015, 24, 5955-5964.	1.4	68
232	Multiple Biopsies and Detection of Cervical Cancer Precursors at Colposcopy. <i>Journal of Clinical Oncology</i> , 2015, 33, 83-89.	0.8	156
233	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, .	0.3	25
234	Exome-Wide Association Study of Endometrial Cancer in a Multiethnic Population. <i>PLoS ONE</i> , 2014, 9, e97045.	1.1	12

#	ARTICLE	IF	CITATIONS
235	Variation in NF- $\kappa$ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1421-1427.	1.1	13
236	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. <i>Human Molecular Genetics</i> , 2014, 23, 6616-6633.	1.4	90
237	p16INK4a Immunohistochemistry in Cervical Biopsy Specimens. <i>American Journal of Clinical Pathology</i> , 2014, 142, 767-772.	0.4	51
238	Cigarette Smoking and Variations in Systemic Immune and Inflammation Markers. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	255
239	Reassurance Against Future Risk of Precancer and Cancer Conferred by a Negative Human Papillomavirus Test. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju153-dju153.	3.0	200
240	Response. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju390-dju390.	3.0	0
241	Seroprevalence of 8 Oncogenic Human Papillomavirus Genotypes and Acquired Immunity Against Reinfection. <i>Journal of Infectious Diseases</i> , 2014, 210, 448-455.	1.9	33
242	Analytic and Clinical Performance of cobas HPV Testing in Anal Specimens from HIV-Positive Men Who Have Sex with Men. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2892-2897.	1.8	29
243	Discovery and validation of methylation markers for endometrial cancer. <i>International Journal of Cancer</i> , 2014, 135, 1860-1868.	2.3	62
244	No Evidence for Synergy Between Human Papillomavirus Genotypes for the Risk of High-Grade Squamous Intraepithelial Lesions in a Large Population-Based Study. <i>Journal of Infectious Diseases</i> , 2014, 209, 855-864.	1.9	46
245	Kernel canonical correlation analysis for assessing gene-gene interactions and application to ovarian cancer. <i>European Journal of Human Genetics</i> , 2014, 22, 126-131.	1.4	33
246	Talc Use and Ovarian Cancer: Epidemiology Between a Rock and a Hard Place. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju260-dju260.	3.0	14
247	Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. <i>Gynecologic Oncology</i> , 2014, 135, 297-304.	0.6	83
248	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt431-djt431.	3.0	186
249	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. <i>Nature Genetics</i> , 2014, 46, 994-1000.	9.4	294
250	Body Mass Index, Physical Activity, and Serum Markers of Inflammation, Immunity, and Insulin Resistance. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2840-2849.	1.1	79
251	Filling a gap in cervical cancer screening programmes. <i>Lancet Oncology</i> , The, 2014, 15, 249-251.	5.1	18
252	Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer. <i>Cancer Cytopathology</i> , 2014, 122, 694-701.	1.4	14

#	ARTICLE	IF	CITATIONS
253	Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic. <i>Journal of Clinical Virology</i> , 2014, 60, 414-417.	1.6	18
254	Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening. <i>Cancer Cytopathology</i> , 2014, 122, 914-920.	1.4	51
255	Heterogeneity of high-grade cervical intraepithelial neoplasia related to HPV16: Implications for natural history and management. <i>International Journal of Cancer</i> , 2013, 132, 148-154.	2.3	28
256	Human Papillomavirus Infection and the Multistage Carcinogenesis of Cervical Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 553-560.	1.1	223
257	Type I and II Endometrial Cancers: Have They Different Risk Factors?. <i>Journal of Clinical Oncology</i> , 2013, 31, 2607-2618.	0.8	613
258	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
259	From Differences in Means between Cases and Controls to Risk Stratification: A Business Plan for Biomarker Development. <i>Cancer Discovery</i> , 2013, 3, 148-157.	7.7	65
260	Triage of HPV-positive women in cervical cancer screening. <i>Lancet Oncology</i> , The, 2013, 14, 107-109.	5.1	32
261	Endometrial Cancer Risk Factors by 2 Main Histologic Subtypes. <i>American Journal of Epidemiology</i> , 2013, 177, 142-151.	1.6	84
262	A Comparison of Human Papillomavirus Genotype-Specific DNA and E6/E7 mRNA Detection to Identify Anal Precancer among HIV-Infected Men Who Have Sex with Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 42-49.	1.1	23
263	2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors. <i>Obstetrics and Gynecology</i> , 2013, 121, 829-846.	1.2	617
264	Methylation of HPV18, HPV31, and HPV45 Genomes and Cervical Intraepithelial Neoplasia Grade 3. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1738-1749.	3.0	119
265	Age at Last Birth in Relation to Risk of Endometrial Cancer: Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium. <i>American Journal of Epidemiology</i> , 2012, 176, 269-278.	1.6	76
266	Human Papillomavirus Load Measured by Linear Array Correlates with Quantitative PCR in Cervical Cytology Specimens. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1564-1570.	1.8	26
267	Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. <i>Aids</i> , 2012, 26, 2185-2192.	1.0	70
268	Screening for anal cancer: endpoints needed. <i>Lancet Oncology</i> , The, 2012, 13, 438-440.	5.1	20
269	Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population. <i>Clinical Cancer Research</i> , 2012, 18, 4154-4162.	3.2	196
270	Human Papillomavirus DNA Methylation as a Potential Biomarker for Cervical Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 2125-2137.	1.1	143



#	ARTICLE	IF	CITATIONS
271	Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. <i>International Journal of Cancer</i> , 2012, 131, 2903-2909.	2.3	51
272	p16 <sup>INK4a</sup> immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities. <i>Cancer Cytopathology</i> , 2012, 120, 294-307.	1.4	70
273	Human Papillomavirus Testing in the Prevention of Cervical Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 368-383.	3.0	583
274	Genetic Variation on 9p22 Is Associated with Abnormal Ovarian Ultrasound Results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>PLoS ONE</i> , 2011, 6, e21731.	1.1	10
275	Hierarchical Clustering of Human Papilloma Virus Genotype Patterns in the ASCUS-LSIL Triage Study. <i>Cancer Research</i> , 2010, 70, 8578-8586.	0.4	25
276	Human Papillomavirus Cofactors by Disease Progression and Human Papillomavirus Types in the Study to Understand Cervical Cancer Early Endpoints and Determinants. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 113-120.	1.1	76
277	A Study of Amplicor Human Papillomavirus DNA Detection in the Atypical Squamous Cells of Undetermined Significance "Low-Grade Squamous Intraepithelial Lesion Triage Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1341-1349.	1.1	20
278	Cervical Cancer Control in the Era of HPV Vaccination and Novel Biomarkers. <i>Pathobiology</i> , 2009, 76, 82-89.	1.9	15
279	Utility of methylation markers in cervical cancer early detection: Appraisal of the state-of-the-science. <i>Gynecologic Oncology</i> , 2009, 112, 293-299.	0.6	247
280	Accuracy of cervical specimens obtained for biomarker studies in women with CIN3. <i>Gynecologic Oncology</i> , 2009, 115, 493-496.	0.6	24
281	Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma. <i>International Journal of Cancer</i> , 2009, 124, 964-969.	2.3	76
282	Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. <i>International Journal of Cancer</i> , 2009, 125, 2151-2158.	2.3	165
283	How to evaluate emerging technologies in cervical cancer screening?. <i>International Journal of Cancer</i> , 2009, 125, 2489-2496.	2.3	91
284	Human Papillomavirus mRNA and p16 Detection as Biomarkers for the Improved Diagnosis of Cervical Neoplasia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2536-2545.	1.1	224
285	No Metastatic Cervical Adenocarcinomas in a Series of p16INK4a-Positive Mucinous or Endometrioid Advanced Ovarian Carcinomas. <i>International Journal of Gynecological Pathology</i> , 2008, 27, 18-23.	0.9	21
286	Biomarkers in Cervical Cancer Screening. <i>Disease Markers</i> , 2007, 23, 315-330.	0.6	175
287	Expression of an endogenous retroviral sequence from the HERV-H group in gastrointestinal cancers. <i>International Journal of Cancer</i> , 2007, 121, 1417-1423.	2.3	49
288	Identification of high-grade cervical dysplasia by the detection of p16INK4a in cell lysates obtained from cervical samples. <i>Cancer</i> , 2006, 107, 2307-2313.	2.0	38

#	ARTICLE	IF	CITATIONS
289	Triage of women with ASCUS and LSIL cytology. <i>Cancer</i> , 2006, 111, 58-66.	2.0	74
290	Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples. <i>Cancer</i> , 2005, 105, 461-467.	2.0	95
291	Identification of differentially expressed genes in colorectal adenoma compared to normal tissue by suppression subtractive hybridization. <i>International Journal of Oncology</i> , 2004, 24, 987-94.	1.4	15
292	Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions. <i>Oncogene</i> , 2002, 21, 419-426.	2.6	126